Stock DNA
Pharmaceuticals & Biotechnology
GBP 2,097 Million ()
14.00
NA
0.00%
19.79
-80.17%
-11.18
Revenue and Profits:
Net Sales:
226 Million
(Quarterly Results - Jun 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.36%
0%
60.36%
6 Months
29.91%
0%
29.91%
1 Year
49.52%
0%
49.52%
2 Years
-34.04%
0%
-34.04%
3 Years
-20.18%
0%
-20.18%
4 Years
65.07%
0%
65.07%
5 Years
107.02%
0%
107.02%
Indivior PLC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
50.10%
EBIT to Interest (avg)
3.31
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
2.35
Tax Ratio
14.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.70%
ROCE (avg)
0
ROE (avg)
569.74%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
-11.18
EV to EBIT
8.04
EV to EBITDA
7.84
EV to Capital Employed
-6.28
EV to Sales
2.18
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 7 Schemes (8.15%)
Foreign Institutions
Held by 53 Foreign Institutions (21.56%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
226.10
237.00
-4.60%
Operating Profit (PBDIT) excl Other Income
55.40
36.50
51.78%
Interest
11.20
7.10
57.75%
Exceptional Items
0.00
-126.80
100.00%
Consolidate Net Profit
13.50
-76.90
117.56%
Operating Profit Margin (Excl OI)
235.10%
140.50%
9.46%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -4.60% vs 7.48% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 117.56% vs -346.47% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
929.70
879.30
5.73%
Operating Profit (PBDIT) excl Other Income
244.90
230.10
6.43%
Interest
32.10
30.60
4.90%
Exceptional Items
-194.10
-212.40
8.62%
Consolidate Net Profit
1.60
1.60
Operating Profit Margin (Excl OI)
239.10%
236.00%
0.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.73% vs 20.21% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.00% vs 103.72% in Dec 2023
About Indivior PLC 
Indivior PLC
Pharmaceuticals & Biotechnology
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.
Company Coordinates 
Company Details
103-105 Bath Road , SLOUGH None : SL1 3UH
Registrar Details






